['exposure to Janus kinase (JAK) inhibitors', 'linked to the occurrence of major adverse cardiovascular events (MACEs)', 'major adverse cardiovascular events (MACEs)']
['F. prausnitzii strains and its extracts', 'reduce blood glucose levels, percent HbA1c, and improve glucose tolerance', 'diabetic and prediabetic mice']
['PD-1/PD-L1 imbalance', 'RO:0002610', 'ulcerative colitis']
['exposure to adalimumab therapy', 'response to', 'IL1B gene']
['thalidomide', 'effect on', 'candidate altered pathways']
['FCP POCT', 'measured with', 'faecal calprotectin']
['exposure to a nanomedicine', 'targeted modulation of gut microbiota-brain interactions', 'gut microbiota-brain interactions']
['hAECs', 'regulate', 'the balance of Th17/Treg cells']
['treatment induction', 'after', 'patients with inflammatory bowel disease']
['SSZ (Sulfasalazine)', 'inhibiton of xCT', 'HGNC:11059']
['PR1P', 'may represent a novel therapeutic approach to preserve', 'VEGF signaling and inhibit inflammation in acute and chronic inflammatory diseases']
['exposure to pyrimidine-5-carboxamide derivatives', 'inhibit', 'SIK1/2']
['time required to care for patients', 'NA', 'primary care']
['PPAR-γ inhibition', 'blocked', 'effects of EPP']
['CHEBI:27300', 'has the potential to improve', "the inflammatory status and immune environment of patients with Crohn's disease"]
['CHEBI:16243', 'recapitulate', 'regulatory effect']
['C. tropicalis', 'had a positive correlation with', 'pediatric CD activity index (PCDAI)']
['larger studies', 'needed to verify', 'these results']
['diosmetin', 'relieves', "TNBS-induced Crohn's disease-like colitis"]
['PopPK and E-R analyses', 'indicated', 'that the inadequate efficacy of tesnatilimab in CD was unlikely due to insufficient drug exposure and target engagement']
['Cornus mas L. Extract', 'Targets', 'the Specific Molecules of the Th17/Treg Developmental Pathway']
['macrocytic anemia', 'combination therapy with methotrexate', 'pediatric patients with inflammatory bowel disease']
['analgesic effects', 'of OJS are', 'not mediated by macrophage TNFα']
['T cell-related features', 'targeting', "patients with Crohn's disease"]
['crocin', 'has', 'anti-apoptotic and anti-inflammatory effects']
['α4β7', 'treatment on', 'intestinal wound healing']
['vascular endothelial cells', 'targeting', 'is a promising emerging therapeutic option']
['ICGA-A', 'treating', 'UC']
['CHEBI:16962', 'loaded in', 'stearoyl ascorbic acid based nanostructured lipid carriers (NLCs)']
['IEC-associated UPR', 'emerges from', 'intestinal Th17 cell differentiation']
['ALA-PDT', 'downregulated', 'subcellular levels of cytokines and exosomes associated with inflammation']
['Tofacitinib', 'fails to prevent', 'T cell transfer colitis']
['CHEBI:26833', 'under exclusive licence to', 'Sociedade Brasileira de Microbiologia']
['IL-10 levels', 'relationship between IL-10 levels and patients', 'patients']
['Yiyi Fuzi Baijiang formula', 'treat', 'ulcerative colitis']
['response to anti-TNF therapy', 'associated with', 'IL17A gene']
['VTE diagnosis', 'increased', 'due to missed diagnoses prior to implementation of the protocol and increased risk awareness after the protocol was established']
['exposure to anti-TNF biologics', 'treatment of inflammatory bowel disease', 'HGNC:87']
['Methotrexate and aminosalicylates', 'have', 'the opposite effect']
['Exposure to chemical toxins', 'Association with gene expression', 'NA']
['Neutrophil-to-Platelet Ratio', 'in therapy of', 'ulcerative colitis']
['Treg differentiation of spleen cells', 'is', 'the mechanism by which geniposide alleviates intestinal inflammation and barrier injury in UC']
['lymphocyte populations', 'associated with', 'FD']
['\'"exposure to"\'', '\'"modulate"\'', '\'"S1PRs"\'']
['functional ingredients', 'suggested as mediators of', 'leaky gut-related disorders']
['Quercetin administration', 'has effect on', 'ulcerative colitis model in mice']
['ABX464 (Obefazimod)', 'upregulating', 'miR-124']
['MPV', 'reflected', 'inflammatory activity']
['Pentosan Polysulfate', 'used for', 'inner bladder wall cracks']
['exposure to poly-D-3-hydroxybutyric acid', 'upregulation of regulatory T-cells', 'Tregs']
['Clostridiales frequency', 'normalized', 'NCI rats']
['thioguanine', 'not associated with', 'adverse maternal or neonatal outcomes']
['activation of FXR', 'regulation of innate lymphoid cells (ILCs)', 'HGNC:10626']
['CHEBI:48113', 'alleviated', 'gut barrier injury and increasing regulatory T cells (Tregs)']
['XLP (Xianglian pill)', 'exerts therapeutic effects on UC', 'gut microbiota-succinate-Treg differentiation axis']
['Methylation of cg22736354', 'is associated with', 'reduced azathioprine inactivation and increased TGN concentrations']
['patients', 'on', 'biologics']
['L-fucose', 'promoted', 'regeneration of intestinal stem cells']
['eosinophils and plasma cells', 'predict', 'Ulcerative colitis']
['myristicin', 'elevated', 'HGNC:7782']
['study', 'develop', 'preventive and therapeutic strategies']
['subjects', 'had treatment-emergent adverse events (TEAEs),', 'all of which were upper respiratory tract infections']
['patients with high monocyte counts', 'experienced relapse', 'discontinuation of biologics']
['hydrolyzable tannins', 'may have potential impact on', 'gut microbiota']
['plasma from IBD patients', 'increase', 'ICAM-1 expression']
['Cur', 'increased', 'BLNK and p-BLNK expression']
['PAMK treatment', 'dependent on', 'inhibition of the IL-6/STAT3 signaling pathway']
['anti-TNF-treated patients', 'developed', 'inadequate T cell responses']
['macrophage', 'RO:0002610', 'inflammatory reaction']
['Berberine', 'RO:0002211', 'gut microbiota']
['combination therapy', 'use of', 'ustekinumab']
['results', 'results of', 'the study']
['vestibulodynia', 'RO:0002264', 'women']
['herbicide propyzamide', 'increases', 'inflammation']
["Crohn's disease", 'treatment with', 'vedolizumab']
['CHEBI:25812', 'caused improvement than', 'naringine']
['lymphoma', 'risk of', 'pediatric patients treated for inflammatory bowel disease']
['hypertension', 'is a rare adverse reaction in the treatment of', "Crohn's disease"]
['CHEBI:3962', 'RO:0002211', 'Breg cells']
['interleukin-22', 'RO:0002211', 'neutrophil recruitment']
['QCWZD', 'inhibit', 'IL-6-STAT3 pathway']
['MMP-9/NGAL complex analysis', 'helpful for', 'better stratification of IBD patients who may benefit from anti-MMP-9']
['CHEBI:17968', 'therapeutic effect of', 'butyrate']
['TNF antagonist therapy', 'treatment response', 'gene expression and DNA methylation']
['QCHS', 'provide', 'further evidence for the application of QCHS in UC treatment']
['low dose ESM-iBET', 'accumulates in', 'CES1-expressing cells']
['antiTNF agents', 'independent variable in correcting anemia', 'treatment of IBD']
['anti-SARS-CoV-2 S1 RBD antibody concentrations', 'associated with', 'infliximab, tofacitinib, and thiopurine']
['patients', 'with', 'HGNC:87']
['compounds 7b and 13b', 'counteracted', 'increased levels of RORγt, STAT3, CCR6, IL-6, IL-17, IL-23, TNF-α, and PGE2']
['breath test', 'positive', 'Patients']
['enzymatically- degraded POS', 'maintaining', 'intestinal homeostasis']
['azathioprine', 'therapeutic monitoring of', 'gene']
['exposure to infliximab', 'treatment response to', "Crohn's disease"]
['combination drug therapies', 'recommended to be considered', 'IL-18 inhibition']
['infliximab (IFX)', 'pharmacokinetics (PK)', 'pediatric acute severe ulcerative colitis (ASUC)']
['placebo response rates in clinical trials of ulcerative colitis (UC)', 'affect', 'normal serum C-reactive protein and albumin and baseline endoscopic severity']
['cycloastragenol', 'modulating', 'SphK/MIP-1α/miR-143 signalling']
['exposure to anti-TNFα (infliximab)', 'stopping', 'immune-related proteins, LAG3, SH2B3, SIT1, IL-10, HSD11B1, CDSN, CNTNAP2, CXADR, ITGA11, IL-6, IL12RB1, CLEC4A, CLEC4C, CLEC7A, LAMP3']
['possibility', 'must always be considered', 'secondary or concomitant autoimmune diseases']
['miR-302d-3p/VEGFR3/AKT axis', 'regulate', 'lymphangiogenesis']
['therapeutic management', 'RO:0002502', 'symptoms and the most likely cause of the disease']
["Crohn's disease recurrence", 'comparing', 'first surgery and relapse clinical conditions']
['ambroxol', 'decreased', 'the susceptibility of the injured colon to apoptosis']
['JY4', 'interfere with the NF-κB-p65 signaling pathway', 'NF-κB-p65']
['prevalence of colorectal cancer', 'was', 'higher in elderly onset IBD']
['APS', 'alleviated', 'UC']
['CHEBI:44185', 'associated with', 'erythrocyte MTX-PGtotal concentration']
['tissue damage', 'reduced', 'DSS-induced UC']
['isomaltulose', 'alleviates', 'acute colitis']
['eosinophils', 'targets', 'IBD treatment']
['CHEBI:17489', 'expression of', 'reduced gene and protein expression of cAMP']
['mRNA-based vaccines', 'receiving', 'patients treated with thiopurines']
['interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α)', 'determined using', 'enzyme linked immunosorbent assay']
['Sanhuang Xiexin decoction', 'regulated', 'intestinal inflammation']
['inflammatory bowel disease (IBD)', 'therapeutic target', 'formyl peptide receptor 2 (FPR2/ALX)']
['Hedgehog signaling', 'RO:0002211', 'Th17 polarization']
['complication of UC', 'should be considered when', 'diarrhea and hematochezia']
["Crohn's disease", 'associated with', 'ustekinumab']
['exposure to angiogenesis', 'interdependent relationship', 'inflammation']
['etrolizumab-s', 'induce', 'residual trafficking of Treg cells']
['CHEBI:15366', 'induced ulcerative colitis', 'rats']
['live-attenuated vaccinations', 'be postponed until the drug is cleared', 'the drug']
['PC', 'provides evidence of', 'effectiveness against UC (ulcerative colitis)']
['UC mouse models', 'were given', '3% dextran sulfate sodium (DSS)']
['Polydatin', 'inhibiting', 'HGNC:11364']
['Astragaloside IV', 'alleviates', 'ulcerative colitis']
['mineralocorticoid receptor deficiency', 'ameliorates', 'DSS-induced colitis']
['familial Mediterranean fever', 'related to', 'gene']
['beclomethasone dipropionate', 'exposure to', 'HGNC:14350']
['CTS', 'may be', 'a promising candidate drug for the treatment of UC']
['TAS-116/metformin', 'effectively degrades', 'HGNC:16400']
['main components of HLHPD', 'analyzed by', 'molecular docking']
['Dasatinib-induced colitis', 'share histologic features including', "Crohn's disease"]
['diarrhoea', 'characterized by', 'Irritable bowel syndrome with diarrhoea (IBS-D) and functional diarrhoea (FDr)']
['GSPE', 'increases', 'residence time of the active components in the body']
['lactoferrin', 'decreased', 'IL-6 and hepcidin levels']
['IBD (Inflammatory bowel disease)', 'interactivity between genetic disposition', 'environmental factors such as bacterial agents']
['drug-induced liver injury', 'redeveloped even after re-switching from', 'CT-P13']
['CD26 inhibitors', 'treatment of', 'UC']
['FIT and PGE-MUM', 'predict', 'relapse of ulcerative colitis']
['Jumping translocation', 'involving', 'chromosome 13q']
['CSR (Celastrol)', 'may be', 'a promising therapeutic drug for UC']
['thromboprophylaxis', 'appropriate in', 'hospitalised paediatric IBD patients']
['was inversely associated with', 'were noted between', 'the mean 24-h measurements of systolic blood pressure, diastolic blood pressure, and heart rate']
['exposure to azathioprine and/or mesalazine', 'treated with', 'azathioprine and/or mesalazine']
['exposure to trifolirhizin', 'regulates the balance of Th17/Treg cells and inflammation in', 'UC mice']
['eosinophils', 'target', 'Vedolizumab']
['HQD', 'certain protective effect on', 'rats with damp heat ulcerative colitis']
['interleukin-23', 'promoter of chronic intestinal inflammation', 'not specified']
['serum zonulin', 'correlates with', 'underlying enteropathies']
['CDC42', 'serve as', 'potential biomarker for monitoring disease progression and IFX response in UC patients']
['empagliflozin', 'use for management of neutropenia/neutrophil dysfunction in patients with GSD Ib', 'GSD Ib']
['exposure to Withania somnifera bioactives', 'RO:0002264', 'GPCR receptors']
['Bacteroides, Escherichia-Shigella, Eubacterium nodatum, Turicibacter, and Clostridium sensu stricto 1', 'showed positive correlations with', "intestinal disorders' parameters"]
['CB2 and TRPV1 receptors', 'Modulating', 'Iron metabolism.']
['1,5-Disubstituted Acylated 2-Amino-4,5-dihydroimidazoles', 'inhibit', 'ROR receptors (RORα/γ)']
["2', 4'-Dihydroxy-2,3-dimethoxychalcone", 'pharmacological inverse agonist of RORγt', 'RORγt']
['Montelukast monotherapy', 'may be considered as a first line treatment for', 'eosinophilic duodenal lesions']
['Interleukin-36β', 'exacerbates', 'acute colitis']
['CHEBI:6801', 'prevention and treatment of', 'certain diseases']
['composite Sophora colon-soluble capsule', 'manages the ratio between', 'NCR+ ILC3s and Lti ILC3s']
['Bupi Yichang Pill', 'RO:0002211', 'homeostasis of follicular helper T cells']
['preoperative treatments with biologics', 'influence of', 'surgical morbidity']
['serum selenium concentration', 'is inversely associated with', 'disease activity-related parameters']
['AJM300 (carotegrast methyl)', 'antagonist of α4-integrin', 'α4-integrin']
['Acute transverse myelitis', 'related to', 'Ulcerative colitis']
['α4β7 and MAdCAM-1', 'play', 'role in human placentation']
['TNBS-Induced Ulcerative Colitis', 'treatment with', 'Boric Acid and Bacillus clausii']
['Sishen Pills, Ershen Pills, Wuweizi Powder, mesalazine, DSS solution, STAT/SOCS signaling pathway, T follicular helper cell, ulcerative colitis', 'regulatory effect, mechanism, induce, increase, decrease, reduce, rise, alleviate', 'Tfr/Tfh9/Tfh17 cells, body mass, colon mass, colon mass index, colon length, unit colon mass index, pathological injury of colon tissue, expression levels of molecules related to the STAT/SOCS signaling pathway, differentiation levels of Tfh cells, p-STAT3, STAT3, p-STAT6, STAT6, SOCS1, SOCS3']
['CHEBI:15365', 'stopping', 'therapy']
['V7 and ANX1', 'present', 'better therapeutic effect than monotherapy']
['Wumei Baijiang prescription', 'regulate', 'Treg/Th17 immune balance']
['NUDT15 loss-of-function variants', 'associated with', 'thiopurine-related adverse events']
['BBR', 'serves as', 'a potential gut microbiota modulator and mucosal barrier protector for UC prevention and therapy']
['chronic use of PPIs', 'may be associated with', 'ICI colitis']
['eosinophils', 'be a prognostic marker of disease outcome in', 'ulcerative colitis']
['exposure to MAdCAM-1', 'costimulates', 'T cells']
['Lycium barbarum Polysaccharides and Capsaicin', 'reduce', 'serum IL-6, colonic TNF-α and TRPA1 protein']
['C3G', 'may be', 'a promising daily supplement for ameliorating impaired fertility caused by colitis']
['several inflammatory biomarkers', 'decreasing', 'sibofimloc']
['CHEBI:28787', 'considered as', 'an effective candidate for the treatment of UC patients']
['CHEBI:3962', 'improving', 'composition of the intestinal microbiota']
['Rhein', 'treats', 'ulcerative colitis']
['subcutaneous injection of infliximab CT-P13', 'results in', 'stable drug levels within 14-day treatment cycle']
['compound 33', 'similar efficacy to', 'positive control 5-aminosalicylic acid']
['Bifidobacterium longum selenium-enriched mutants', 'recommended as anti-inflammatory and immunomodulatory supplements', "'-'"]
['GlcCer nanoparticles', 'potential efficacious therapeutic target for', 'IBD patients']
['exposure to oleanolic acid', 'antagonizing the human RORγT nuclear receptor', 'RORγT gene']
['KD', 'led to', 'a compensatory downregulation of TrkB to maintain a physiological steady state']
['Berberine treatment', 'suppresses', 'cecal ligation and puncture induced intestinal injury']
['Sphincter of Oddi dysfunction', 'is misdiagnosed as', 'familial Mediterranean fever']
['DNBS-induced colitis', 'in the mitigation of', 'ELv']
['WMD', 'RO:0002211', 'dysbiosis of gut microbiota']
['biologic therapies', 'regulate', 'chemokine network gene expression']
['oncostatin-M', 'predicts', 'lack of clinical remission']
['VK - Vitamin K', 'role in intestinal health', 'intestinal health']
['activated immune cells', 'promising for selective drug release', 'immune cells']
['CHEBI:6801', 'may be potential therapeutic agents for the treatment of', 'HGNC:87']
['gut microbiota', 'role', 'onset of autoimmune diseases']
['PR3-ANCA measurement', 'is useful for', 'evaluating disease severity and extension and predicting the clinical course']
['Naticol®Gut', 'restored', 'anti-inflammatory and anti-oxidant phenotype']
['LMPD (lymphoid and myeloid proliferative disorder)', 'associated with', 'HGNC:87']
['exposure to Retinoic Acid Receptor-Related Orphan Receptor γ-t/Dihydroorotate Dehydrogenase Dual Inhibitors', 'dual-targeting approach', 'HGNC:2867']
['postbiotics', 'beneficially modulate', 'immunological response and inflammation']
['vaccines', 'should be delayed for', 'at least 6 months or until the serum level of the medication is undetectable']
['colitis', 'induced by', 'dextran sulfate sodium']
['IL13RA2', 'is a potential biomarker to predict', 'anti-TNF-α treatment response']
["Crohn's disease", 'of small intestine', "small bowel Crohn's disease"]
['inflammatory bowel disease', 'is associated with', 'attenuated IgA and neutralisation responses to SARS-CoV-2']
['SIRT1 blockade', 'aggravated', 'TNBS-induced colitis']
['Acute kidney injury (AKI)', 'linked to', 'interstitial nephritis secondary to anti-inflammatory drugs']
['clinical practice', 'should be considered in', 'preserve kidney function and ensure the best approach to our patients']
['Painong powder', 'RO:0001019', 'Platycodonis Radix']
['need', 'increase', 'awareness and implementation of international guidelines on iron supplementation']
['brain-gut axis', 'in', 'HGNC:9005']
['DSS-induced colitis', 'contained the human Id2 gene', 'HGNC:6018']
['PIBD (Paediatric onset IBD)', 'associated with malignancy', 'cancer']
['vitamin C deficiency', 'result in', 'HGNC:4695']
['Mesalamine', 'loaded with', 'Saccharomyces boulardii']
['Henoch-Schönlein purpura', 'induced by', "infliximab for Crohn's disease"]
['Dextran Sodium Sulfate', 'model of colitis', 'Mouse']
['some rare events', 'can lead to', 'outcomes.']
['conivaptan', 'anti-inflammatory role of', 'conivaptan']
['5-aminosalicylate acid (5-ASA)', 'related to', 'HGNC:3642']
["Crohn's Disease and Early Exposure to Thiopurines", 'are Independent Risk Factors for Mosaic Chromosomal Alterations', 'in Patients with Inflammatory Bowel Diseases']
['IL-6', 'prognostic for', 'endoscopic response']
['C60 fullerene suspension', 'reduces', 'levels of histamine and prostaglandin in the rat blood']
['exposure to Tyk2 inhibition', 'therapeutic advantage', 'treating autoimmune and chronic inflammatory diseases']
['vaccine serologic response longevity in this group', 'may be limited', 'gene']
["Small bowel adenocarcinoma in Crohn's disease", 'associated with', "Crohn's disease"]
['Etrolizumab-positive lymphocytes (E-Ly)', 'associated with', 'higher HAS (histologic activity score)']
['study', 'is required to validate', 'these observations']
['Preclinical studies', 'exploration of', 'repurposed tegaserod']
['baicalein', 'promoted', 'expression of tight junction proteins ZO-1 and occluding']
['HCTZ and Dicyclomine Induced Uncharacteristic Contraction Alkalosis', 'driven by drug-drug interaction between', 'dicyclomine and HCTZ']
['possibility of sarcoidosis', 'be aware of', 'clinicians']
['ESM-HDAC528', 'improve', 'colitis']
['GPR65 (TDAG8)', 'inhibits', 'intestinal inflammation and colitis-associated colorectal cancer development']
['CD40-CD40L pathway', 'targets', 'B-cell genes']
["exposure to Crohn's disease", 'patients with', "Crohn's disease"]
['exposure to infliximab', 'induces', 'annexin A1']
['Neo', 'serve as a lead for developing', 'therapeutics']
['IGF-1', 'could prove to be successful in reducing', 'disease pathology']
['Rac1/pSTAT3 expression', 'marker of the thiopurine effect', 'thiopurine therapy']
['PARP inhibitor olaparib', 'improves', "experimental Crohn's Disease"]
['GPR120', 'positively correlated', 'Gpr120 expression with Il10 expression']
['Akkermansia muciniphila', 'RO:0002211', 'tryptophan metabolism']
['cannabis extracts', 'reduced', 'FAAH expression levels']
['RORα', 'regulating', 'T cell infiltration']
['Mevalonate Kinase Deficiency', 'cause of', 'Severe Very-Early-Onset Inflammatory Bowel Disease']
['RBC 6-TGN measurements', 'correlate with', 'laboratory result abnormalities']
['Vedolizumab levels', 'impact', 'postoperative outcomes']
['exposure', 'to', 'drugs']
['exposure to ferroptosis-related genes', 'related to', 'ulcerative colitis (UC)']
['local delivery of high 1,25(OH)2D concentrations', 'promising strategy to augment', 'intestinal epithelial repair']
['CHEBI:17968', 'inhibits', 'neutrophil-associated immune responses such as proinflammatory mediators and NET formation']
['exposure to BI 706039', 'functional inhibitor of both human and mouse RIPK2', 'HGNC:10020']
['SJMHE1', 'inhibits', 'acute and chronic colitis']
['infliximab concentrations', 'are correlated with', 'outcome']
['drug-related pneumonitis', 'is an adverse effect of', 'several drugs']
['α4β7 and αEβ7 blockade', 'promotes reduction', 'gut mucosa']
['OPS-2071', 'antibacterial activity', 'IBD-related bacteria']
['vedolizumab', 'exposure-efficacy', 'T cells']
['peripheral blood CD70+ T cells', 'was significantly reduced by treatment with', 'anti-TNFα antibodies']
['musculoskeletal deficits', 'associated with', 'children and adults with IBD']
['PF-06480605', 'can engage and inhibit', 'colonic TL1A, targeting inflammatory T cell and fibrosis pathways']
['vaccination', 'exposure to', 'SARS-CoV-2']
['IgA vasculitis', 'association of IgAV and IBD', 'HGNC:87']
['TPMT and NUDT15 polymorphisms', 'implicated as the predominant cause of', 'thiopurine induced leukopenia']
['exposure to microbial natural products and synthetic ligands', 'modulate', 'immune cells called mucosal associated invariant T cells (MAIT cells)']
['patient', 'improved', 'symptoms']
['CHEBI:49200', 'was associated with', 'increased risk of ulcerative colitis']
['binding assays', 'are appropriate for therapeutic drug monitoring', 'therapeutic drug monitoring']
['Milk-derived extracellular vesicles', 'alleviate', 'ulcerative colitis']
['serum biomarkers', 'associated with PNR', 'HGNC:2367']
['UST therapy', 'suppresses', 'Th17 cell differentiation']
['CHEBI:27568', 'controls', 'T cell differentiation']
['colonic acute graft-versus-host disease', 'or', "colonic Crohn's disease"]
['UC patients at CR status', 'showed', 'high TW1 expression in neutrophils']
['acetic acid-induced colitis', 'alleviates', 'oxidative stress, inflammation, apoptosis']
['doses of ECU', 'may be necessary', 'maintain therapeutic blood levels of ECU and full complement blockade']
['Mastiha', 'influenced considerably the metabolic profile of', 'IBD patients']
['PLGA-RMP', 'deserves further consideration as a potential therapeutic nanomedicine to treat', 'various inflammatory diseases, including IBD']
['opioid tone', 'RO:0002326', 'protection']
['IF1 gene', 'inactivation', 'neutrophil infiltration']
['Tryptophan metabolites', 'modulate', 'inflammatory bowel disease and colorectal cancer']
['tricin', 'relieved', 'increased population']
['CGD', 'should to be considered in', 'patients with proven C. lusitaniae infection']
['Adalimumab', 'influence', 'mucosal healing and loss of response']
['icariin', 'modulating', 'p-p65/p65 Molecule']
['colonic intestinal inflammation', 'is predisposed to by increased IL-2 signaling', 'colonic intestinal inflammation']
['miR-155', 'did not change significantly in the', 'Mastiha group in patients with less advanced fibrosis']
['Tec kinase ITK', 'RO:0002331', 'T cell-mediated colitis']
['platelet FcγRIIA', 'is probably tuned by its affinity for', 'IgG2']
['inflammatory bowel disease', 'predicts', 'failure in patients with IBD']
['Patients With Inflammatory Bowel Disease', 'have', 'Messenger RNA COVID-19 Vaccines']
['rCsHscB', 'produce therapeutic effect on', 'DSS-induced chronic ulcerative colitis in mice']
['healthy FS-treated macrophages', 'suppress cluster of differentiation 4+ T-cell activation and interferon γ secretion', 'UC remission FS-treated counterparts']
['exposure to hydroethanolic extract of Maesa lanceolata leaves', 'efficacy on acetic acid-induced colitis', 'acetic acid-induced colitis']
['Albumin-to-Globulin Ratio', 'associated with', 'relapse']
['DSS-induced colitis', 'model of', 'colitis severity']
['administration of Pin1 inhibitor', 'partially but significantly prevented', 'DSS-induced colitis in mice']
['GSTP1 SNP', 'may be a predictive marker for', 'small bowel bleeding']
['adalimumab therapy', 'impact on quality of life (QoL)', 'adult anti-TNF-naïve patients with moderately-to-severely active CD']
['NLR (neutrophil-to-lymphocyte ratio), PLR (platelet-to-lymphocyte ratio), ELR (eosinophil-to-lymphocyte ratio), ENLR (eosinophil*neutrophil-to-lymphocyte ratio)', 'predict', 'HGNC:3443']
['acute severe lower gastrointestinal bleeding (LGIB)', 'is associated with', 'HGNC:2505']
['disease management and targeted therapy', 'key for', 'disease management and targeted therapy']
['EMA401', 'improves', 'gut function']
['IBD', 'targeting', 'immune cell trafficking']
['technical challenges', 'help to overcome', 'those challenges']
['outcomes', 'improve', 'in this challenging population']
['clinical symptoms', 'related to', 'hypophosphatemia']
['Crohn Disease', 'associated with', 'autoimmune hemolytic anemia']
['patients with IBD', 'should undergo', 'systematic laboratory tests for anemia or micronutrient deficiencies']
['exposure to enterotoxigenic Bacteroides fragilis toxin (BFT)', 'RO:0002211', 'colonic epithelial cell response']
['Adalimumab biosimilars', 'are equally effective and safe as', 'adalimumab originator']
['food antigen', 'plays a role in intestinal inflammation', 'intestinal inflammation']
['RS102895', 'inhibited', 'colitis in Il6-/- mice']
['galectin-1-induced T-cell death', 'induction of', 'T-cell apoptosis']
['CCR6-CCL20 axis', 'binds to', 'HGNC:1607']
['Phlorizin', 'inhibits', 'sodium-linked glucose transporters (SGLTs)']
['LRG', 'decreased along with improvements in clinical and endoscopic outcomes upon adalimumab treatment', 'serum LRG levels']
['Infliximab exposure', 'associated with reduced', 'IFX clearance']
['immune-metabolism therapy for colitis', 'sets the stage for a new perspective on', 'Th17 cell differentiation']
['infliximab concentrations', 'associated with', 'fistula response, composite remission']
['patients with low XO expression', 'might have a high risk of', 'thiopurine-induced toxicity']
['treatment with anti-TNF-α', 'may help control', 'increased bone resorption']
['exposure to tofacitinib', 'compare', 'HGNC:13709']
['messenger RNA Coronavirus Disease 2019 Vaccines', 'serologic Response', 'inflammatory Bowel Disease Patients']
['Azathioprine', 'modulate', 'redox imbalance']
['IL23/IL17 Pathway', 'role in', "Crohn's Disease"]
['mesalazine-induced neonatal gastrointestinal bleeding', 'cause', 'allergic enterocolitis']
['QCHS granules', 'relieve', 'mucus/bloody stool']
['small intestinal bacterial overgrowth (SIBO)', 'role in the occurrence of IBS', 'irritable bowel syndrome (IBS)']
['CHEBI:38211', 'modulates', 'oxidative stress and inflammatory biomarkers']
['Jiaoqi powder', 'treat', 'ulcerative colitis']
['vedolizumab levels', 'associate with', 'therapy outcomes']
['uncovering', 'offering', 'promising therapeutic strategies']
['the UDCA + Mesalazine group', 'showed', 'lower percentage of Proteobacteria compared to']
['exposure to ChemR23', 'targeted by', 'resolvin E1']
['studies', 'evaluating', 'measures of health care utilization, quality of life (QOL), laboratory indices, biomarkers of inflammation, and serological measures of immunity in patients who received SSC alone or with KB109']
['vitamin D treatment', 'reduces the need for', 'infliximab dose-escalation']
['CHEBI:17968', 'induce regulation of T cell surface expression of CTLA-4', 'HGNC:2505']
['chrysophanol', 'exhibiting', 'a beneficial potential for curing IBD in vivo']
['gut microbiota alterations', 'correlated with blood chemical indices', 'HGNC:10626']
['acupoint catgut embedding', 'inhibit', 'activation of PKC protein']
['Monocyte TREM-1 Levels', 'associate with', 'Anti-TNF Responsiveness in IBD Through Autophagy and Fcγ-Receptor Signaling Pathways']
['steroid therapy', 'risk factor', 'triggering EBV colitis']
['gastrointestinal diseases', 'associated with', 'altered intestinal permeability']
['α-TREM-1 agonistic antibody', 'modulates the function of', 'neutrophils and macrophages']
['altered TNFRSF1B, FCGR3A, and IL1B genes expression', 'can be a predictor of the primary non-response to', 'anti-TNF therapy']
['EEN-3PUFAs', 'regulated', 'putative mechanisms']
['the effects of WSBCW', 'evaluate', 'gastrointestinal disorders, such as IBS and IBD']
['CYP2C19 polymorphism', 'not correlated with', 'the clinical efficacy of AMT for treating IBS-D']
['exposure to anti-TNF therapy', 'involvement in anti-TNF response', 'MMD and ELOVL7 gene regions']
['ulvan-Se', 'suppressed mRNA expression mediated by', 'the nuclear factor kappa B pathway']
['CD-62L (L-Selectin)', 'shedding of', 'granulocytes']
['anti-TNF therapy', 'associated with', 'lower risk of rebleeding compared with CMT']
['MSC-derived exosome', 'improves', 'inflammation']
['Ustekinumab trough levels', 'associated with', 'treatment outcomes']
['Low-Dose IL-2', 'therapeutic efficacy of', 'Treg cells']
['immune cell metabolism', 'manipulating', 'immune cell metabolism']
['exposure to 6-(methylsulfinyl)hexyl isothiocyanate (6-MITC)', 'potential inhibition of glycogen synthase kinase 3 beta (GSK-3β)', 'GSK-3β']
['NAFLD and IBD', 'have a comorbidity of', 'NAFLD and IBD']
['oral Sucrosomial Iron', 'is as effective as', 'intravenous ferric carboxy-maltose']
['Iridoid glycosides', 'gene expression of COX-2 and MMP-9', 'NADPH']
['patient', 'should be managed by', 'ongoing surveillance']
['Hepatic mosaic enhancement pattern (HMEP)', 'RO:0002610', 'HGNC:2505']
['intestinal permeability', 'RO:0002211', 'HGNC:14685']
['AIDs', 'should be provided', 'Internet-based service']
['GQ', 'restore', 'Treg and Th17 cell homeostasis in colonic tissue']
['Cyclosporine', 'alleviation in', 'ASUC patients']
['research', 'registered', "'Iranian Registry of Clinical Trials (IRCT): IRCT20090822002365N17'"]
['dextran sulfate sodium-induced inflammation and colitis in mice', 'are ameliorated by (R)-ketamine', 'TrkB signaling']
['role of innate lymphoid cells', 'may provide ideas for developing', 'novel and targeted approaches for treatment of IBD']
['thiopurine metabolism during pregnancy', 'undefined', 'thiopurine metabolites']
['ICP diagnosis', 'is established', 'this drug']
['adalimumab-induced thrombocytopenia', 'causing', 'severe thrombocytopenia']
['PD-1', 'act as', 'a potential target for the prevention of AP in the future']
["Crohn's disease", 'RO:0002326', 'clinical benefits of JAK1 inhibitor']
['GATA3', 'transcription factor', "Crohn's disease"]
['Listeria monocytogenes bacteremia and meningitis', 'have been reported in', 'HGNC:87']
['BBG/OLT1177', 'exhibited', 'complementary effects and effectively ameliorated UC']
['Schisandrin B', 'decrease', 'HGNC:5981']
['MMF (mycophenolate mofetil)', 'decreased', 'expression of pro-inflammatory cytokines, interleukin (IL)-1β and IL-18']
['thiopurine therapy', 'induces adverse events', 'pediatric inflammatory bowel disease']
['antibody development', 'frequency of late development', 'patients with combined immunosuppressive treatment']
['haem oxygenase 1 (HO-1)', 'exhibits anti-inflammatory properties', 'immunologists']
['IL-10high-producing Treg cells', 'upregulation of', 'the pharmacological inhibition of KCa3.1']
['CHEBI:6801', 'alleviates inflammation in', 'oxazolone induced ulcerative colitis']
['Chemotherapy-Induced Remission', 'Associated With', 'Steroid-Dependent Ulcerative Colitis']
['\'"fever and diarrhea"\'', '\'"association between"\'', '\'"RGS17"\'']
['monocyte counts', 'could help monitor patients', "at least in Crohn's disease"]
['herbal formulae', 'treats', 'JAk2, HIF-1α, and HSP90AB1']
['miR-199a-3p oligomer', 'down regulating', 'IL-17A/IL-23 axis']
['immunotherapeutic strategies', 'have been developed', 'boost or control ectonucleotidase expression and activity in important disease settings']
['treatment of IBD patients', 'for', 'IBD patients']
['acetic acid-induced ulcerative colitis', 'protection against', '6-paradol']
['hsa_circRNA_103765', 'sponging', 'miR-30 family']
['Gut microbiota', 'is mainly related to', 'DNA repair and recombination proteins, ribosome, purine metabolism, peptidases, and pyrimidine metabolism']
['infliximab therapy', 'associated with outcome of', "pediatric Crohn's disease"]
['therapeutic intervention', 'aimed at', 'disease activity']
['Epstein-Barr virus reactivation', 'implicated in refractory UC', 'UC']
['IgA and IgM response to MAP antigens', 'Increased', 'seen in patients exposed to biologic therapy']
['OE-MSCs-Exos', 'promote', 'induction of Treg cells']
['dilodendron bipinnatum extract', 'promotes', 'antioxidant effect']
['is now available', 'at the bedside in real-time', 'within the electronic health record']
['Tong-Xie-An-Chang Decoction', 'treatment of', 'diarrheal irritable bowel syndrome']
['S1P2 pathway', 'potential drug target for immunity-mediated UC', 'immunity-mediated UC']
['BAFF expression', 'is associated with', "Crohn's disease"]
['Dapsone-induced DRESS', 'associated with', 'Human Leukocyte Antigen (HLA)-B:13*01']
['Thiomyristoyl', 'ameliorates', 'colitis']
['exposure to mesalazine', 'induced', 'myocarditis']
['Dipeptidyl Peptidase 4 (DPP4), aminopeptidase N (APN), ectopeptidases', 'significance in inflammatory bowel diseases (IBD)', 'IBD, disease severity']
['loss of response to infliximab dose intensification', 'equivalent to between', '22.9 and 41 AU/mL on the Promonitor assay']
['study', 'provided a feasible method for discovering potential drugs from', 'traditional Chinese medicine formulations']
['Vedolizumab exposure', 'explain', 'non-response']
['Hydroalcoholic extract of Tagetes minuta L.', 'inhibits', 'inflammatory bowel disease']
['further treatment interval', 'RO:0002507', 'sonographic measurement of BWT at week 8']
['exposure to IL17-, NOD-, and Oncostatin-M-signalling pathways', 'upregulated in TN-CD patients', 'genes']
['MF (mycosis fungoides)', 'relationship between MF and UC (ulcerative colitis)', 'UC (ulcerative colitis)']
['thalidomide', 'targeting', 'VEGF and Ang-2']
['exposure to dextran sulfate sodium (DSS)-induced colitis', 'alleviate', 'colitis in both acute and chronic DSS mouse models.']
['Breg and Treg cells', 'predictive value for the effect of Infliximab', 'the effect of Infliximab']
['ADA', 'was estimated to increase', 'vedolizumab linear clearance']
['Drug-induced IgA vasculitis', 'induce', 'IgAV']
['Glucocorticoid-induced hyperglycaemia', 'complication of GC treatment', 'IBD patients']
['PE', 'has a beneficial effect on', 'ulcerative colitis']
['previous biologic therapy', 'may', 'have altered the sequestration capacity of circulating exosomes.']
['CHEBI:3962', 'RO:0002211', 'Treg/Th17 signaling pathway']
['vitamin D3', 'reduce', 'therapeutic effects of rifaximin']
['JAK/STAT pathway', 'involvement', 'UC pathogenesis']
['AELPL', 'has', 'antioxidant and anti-inflammatory activities']
['Gpr183', 'knockout strongly reduced accumulation of intestinal lymphoid tissue in', 'health and all colitis models']
['microbiota and metabolome', 'are different', 'between responders and non-responders']
['DSS-induced colitis', 'inhibiting', 'production of pro-inflammatory chemocytokines']
['high ATI titers', 'found in', 'patients']
['FYC', 'affecting', 'inflammatory factors']
['NUDT15 C415T variant', 'compared with', 'TPMT genotyping']
['Infliximab treatment', 'weight gain', "Crohn's disease patients"]
['Anti-TNF Therapy', 'response to', 'collagen turnover']
['serum VDZ concentration threshold', 'associated with', 'endoscopic remission']
['Infliximab clearance', 'decreases', 'in the second and third trimesters']
['Fg', 'induced activation of', 'HGNC:391']
['citrulline supplementation', 'has protective effects on', 'ulcerative colitis']
['arthritogenic variants of PTPN2', 'amplify the link between', 'gut inflammation and arthritis']
['chlorogenic acid', 'regulates inflammation in IL-10 knockout mice', 'IL-10 knockout mice']
['clinical outcomes', 'were influenced by', 'the type of compound administered']
['pediatric patients with CD', 'with', 'AITD']
['AAS (anabolic-androgenic steroids) use', 'positive and negative effects', 'health effect']
['Infliximab Trough Levels', 'are not predictive of', 'Relapse']
['IL-23', 'RO:0002211', 'HGNC:5962']
['APT2 or knockout of Zdhhc7', 'relieves', 'the symptoms of IBD']
['LILRA3', 'functions as an', 'anti-inflammatory modulator']
['TYK2i', 'reduced', 'human Th1 differentiation']
['Sulfasalazine', 'used as a standard-of-care in ulcerative colitis', 'ulcerative colitis']
['Paracentral acute middle maculopathy (PAMM)', 'associated with', 'ulcerative colitis (UC)']
['exposure to synbiotic (Syngut)', 'effect of treatment with', 'experimental colitis under stress conditions']
['NKp44+ ILC3', 'contribute to', 'homeostasis of intestinal mucosa']
['BA-BBR NPs', 'provide a basis', 'BA-BBR NPs']
['Adipokine resistin levels at time of pediatric Crohn disease diagnosis', 'predict', 'escalation to biologic therapy']
['pediatric and adult ulcerative colitis', 'DEGs (differentially expressed genes)', '1700 DEGs']
['colitis model', 'injected', 'QCHS-treated DCs']
['pterostilbene (PSB)', 'inhibitory effect', 'DC-mediated T cell proliferation']
['ustekinumab', 'associated with', 'cancer of the thyroid']
['exposure to paeoniflorin', 'attenuates', 'DSS-induced ulcerative colitis']
['\'"improvement in the gut barrier"\'', '\'"results in"\'', '\'"inhibition of visceral pain"\'']
['studies', 'are warranted', 'that evaluate pharmacodynamic biomarker targets for endoscopic and histologic healing']
['CHEBI:63046', 'influence', 'intestinal inflammation']
['theoretical basis', 'provided', 'further study of the effective components and mechanism of IN in the treatment of UC']
['Adalimumab dose intensification', 'compare', 'trough levels of ADA (TLA) and occurrence of anti-ADA antibodies (AAA)']
['orally administered antibody delivery systems', 'improved efficacy in', 'murine colitis']
['EEN', 'downregulating', 'expression of IL-17A in the intestinal mucosa']
['clinical therapeutic potential of GC-C agonists', 'suggests', 'HGNC:87']
['CHEBI:35705', 'use', 'CMV-infected patients']
['NCIT:C2991', 'include', 'platelet-related complications such as psoriasis, atherosclerosis, and inflammatory bowel disease']
['thiopurine withdrawal', 'consideration of', 'on a case-by-case basis']
['QP-IBD patients', 'were less likely to exhibit elevated', 'QP-IBD']
['major adverse cardiovascular events', 'were infrequent', 'the OLE study']
['Increased BDNF level', 'suggests that', 'it may be involved in']
['leukocytoclastic vasculitis induced', 'by', 'infliximab']
['Angiogenin', 'RO:0002211', 'microbiota composition']
['microRNAs', 'be applied for the development of', 'targeted therapies against inflammation-mediated colon cancer']
['inflammatory bowel disease (IBD)', "'-'", "'-'"]
['Creatine kinase levels', 'evaluated', 'tofacitinib-treated patients with UC']
['type I and type II interferon (IFN) signatures', 'can predict the response to Anti-TNF agents', 'gene IFNGs']
['immune-related adverse events', 'treated with', 'HGNC:20595']
['Celecoxib-loaded NLCs', 'alleviate severity of colitis', 'colitis']
['iDose-assisted management', 'achieved', 'clinical remission and cost reduction']
['melatonin supplementation', 'alters', 'gut microbiota']
['eosinophilic gastroenteritis', 'diagnosed with', 'ulcerative colitis']
['loperamide exposure', 'toxicity relationship', 'brain injury']
["Chinese dragon's blood", 'RO:0002211', 'RSK/TSC2/mTOR/ribosome pathway']
['golimumab', 'induced', 'clinical remission']
['thrombotic complications', 'consider', 'cerebral venous system']
['Combination therapy', 'involving VED and GMA', 'IBD patients with EIMs']
['α7-nicotinic receptor agonists', 'are', 'panacea']
['Traditional Chinese Medicine constitution types', 'RO:0002610', 'diseases']
['Saccharomyces cerevisiae and Candida spp. strains', 'interaction with the gut microbiome', "'-'"]
['IRF5', 'associated with', 'pathogenesis']
['Refractory Ulcerative Colitis', 'improved by', 'Scheduled Combination Therapy of Vedolizumab and Granulocyte and Monocyte Adsorptive Apheresis']
['drug-induced ischemic colitis', 'accompanied by', 'ulcerative colitis']
['microbiota perturbation', 'may increase risk of', 'colitis later in life']
['CXCL4-DNA/RNA complexes', 'sustain', 'the SSc IFN-I signature and general inflammation']
['exposure', 'treated by', 'Biologics']
['patients', 'without remission', 'therapeutic efficacy']
